

AGIOS PHARMACEUTICALS INC
 Form 4
 July 30, 2013

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
 Expires: January 31, 2015
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
 Celgene European Investment Co
 LLC

2. Issuer Name and Ticker or Trading Symbol
 AGIOS PHARMACEUTICALS INC
 [AGIO]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction (Month/Day/Year)
 07/29/2013

____ Director
 ____ Officer (give title below)
 10% Owner
 ____ Other (specify below)

86 MORRIS AVENUE

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
 ____ Form filed by One Reporting Person
 Form filed by More than One Reporting Person

SUMMIT, NJ 07901

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/29/2013		C		1,887,473	A	<u>(1)</u> 1,887,473
Common Stock	07/29/2013		C		2,123,453	A	<u>(3)</u> 4,010,926
Common Stock	07/29/2013		P		708,333	A	\$ 18 708,333
						I	See footnote <u>(4)</u>

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form

SEC 1474 (9-02)

displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)		
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount Number Shares
Series B Convertible Preferred Stock	(1)	07/29/2013		C	5,190,551	(1)	(1)	Common Stock	1,887,
Series C-2 Convertible Preferred Stock	(3)	07/29/2013		C	5,839,496	(3)	(3)	Common Stock	2,123,

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Celgene European Investment Co LLC 86 MORRIS AVENUE SUMMIT, NJ 07901		X		
CELGENE CORP /DE/ 86 MORRIS AVENUE SUMMIT, NJ 07901		X		
Celgene Alpine Investment Co., LLC 86 MORRIS AVENUE SUMMIT, NJ 07901		X		

Signatures

/s/Perry Karsen _____ Perry Karsen, Manager
Date: 07/30/2013
**Signature of Reporting Person

Perry Karsen, Executive Vice President and Chief Operations Officer
Date: 07/30/2013
**Signature of Reporting Person

Robert J Hugin, Director
Date: 07/30/2013

__Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Upon closing of the Issuer's initial public offering, each share of Series B Convertible Preferred Stock automatically converted at a ratio of 1-for-2.75 into the number of shares of Common Stock shown in column 7 without payment of further consideration. The shares had no expiration date.

(2) These shares are owned directly by Celgene European Investment Company LLC, a wholly-owned subsidiary of Celgene Corporation ("Celgene"), and Celgene has the power to vote, acquire, hold and dispose of all shares. Celgene disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.

(3) Upon closing of the Issuer's initial public offering, each share of Series C-2 Convertible Preferred Stock automatically converted at a ratio of 1-for-2.75 into the number of shares of Common Stock shown in column 7 without payment of further consideration. The shares had no expiration date.

(4) These shares are owned directly by Celgene Alpine Investment Co., LLC, a wholly-owned subsidiary of Celgene, and Celgene has the power to vote, acquire, hold and dispose of all shares. Celgene European Investment Company LLC and Celgene disclaim beneficial ownership of the securities except to the extent of their pecuniary interest therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.